Here are the 424B prospectus supplements from Braveheart Bio, Inc. (BRVE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BRVE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRVE filings page.
Braveheart Bio, Inc. is conducting an initial public offering of 21,250,000 shares of common stock at $18.00 per share, with expected gross proceeds before expenses of $382.5 million and net proceeds of about $351.2 million. Underwriters have a 30‑day option to purchase up to 3,187,500 additional shares. The stock is approved for listing on the Nasdaq Global Market under the symbol BRVE.
The company is a clinical‑stage biopharmaceutical business focused on hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its lead candidate, BHB‑1893, a cardiac myosin inhibitor, has shown rapid LVOT gradient reduction and limited LVEF impact in Phase 2 studies run by its licensor Hengrui, and is being advanced into global Phase 3 trials in obstructive and non‑obstructive HCM.
Braveheart reported a $14.3 million net loss for the three months ended March 31, 2026 and had an accumulated deficit of $80.3 million, reflecting heavy R&D spending and no product revenue. Pro forma as adjusted for the IPO, cash and cash equivalents would be $431.8 million, to fund Phase 3 programs, supporting R&D, and general corporate purposes. The company highlights substantial risks typical for early‑stage biotech, including ongoing losses and the need for additional capital.